Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Silvia Cretella
Observed names:
S Cretella,
S. Cretella
Institutions:
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola,
University of Bologna
Observed institutions:
Yale University,
IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola,
Ospedale Papa Giovanni XXIII,
University of Bologna
ORCID:
0009-0000-1249-1618
Observed ORCID:
0009-0000-1249-1618
OpenAlex ID:
A5090072507
Safety and Immunogenicity of an Outer Surface Protein A Vaccine in Subjects with Previous Lyme Disease
1995
·
R. T. Schoen
, F. Meurice
, et al.
·
The Journal of Infectious Diseases
·
61
Effectiveness and predictors of treatment discontinuation of long-acting cabotegravir/rilpivirine in virologically suppressed people with HIV: real-life data from the Icona Cohort
2025
·
Roberta Gagliardini
, Sara De Benedittis
, et al.
·
Journal of Antimicrobial Chemotherapy
·
22
A holistic evaluation of patients with chronic Hepatitis D virus (HDV) infection enrolled in the Italian PITER-B and delta cohort
2024
·
Loreta A. Kondili
, Giuseppina Brancaccio
, et al.
·
International Journal of Infectious Diseases
·
15
PDF
Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort
2024
·
Antonella d’Arminio Monforte
, Alessandro Tavelli
, et al.
·
Journal of Antimicrobial Chemotherapy
·
15
PDF
A multicentre real-life prospective cohort study on effectiveness, durability and safety of long-acting injectable cabotegravir and rilpivirine in northern Italy: the LONGITUDE study
2025
·
Maria Mazzitelli
, Claudia Cozzolino
, et al.
·
Journal of Antimicrobial Chemotherapy
·
9
PDF
Efficacy and Safety of Switching to Dolutegravir/Lamivudine in Virologically Suppressed People Living with HIV-1 Aged Over 65 Years
2023
·
Leonardo Calza
, Vincenzo Colangeli
, et al.
·
AIDS Research and Human Retroviruses
·
8
Efficacy and Safety of Dolutegravir/Lamivudine in Antiretroviral Therapy-Naive People Living With HIV-1 and With High-Level Viremia
2025
·
Leonardo Calza
, Vincenzo Colangeli
, et al.
·
JAIDS Journal of Acquired Immune Deficiency Syndromes
·
6
Evaluation of a lyme disease enzyme immunoassay using the 41-G fragment of flagellin
1995
·
S. Cretella
, S. Gordon
, et al.
·
European Journal of Clinical Microbiology & Infectious Diseases
·
6
The Medical Impact of Hepatitis D Virus Infection in Natives and Immigrants: The Italian Paradigm
2025
·
Gian Paolo Caviglia
, Eleonora Dileo
, et al.
·
Liver International
·
5
PDF
Durability of lenacapavir in viremic heavily treatment-experienced people with HIV: real-world data from the PRESTIGIO Registry
2025
·
Tommaso Clemente
, Golnaz Torkjazi
, et al.
·
Journal of Antimicrobial Chemotherapy
·
4
Effectiveness of first-line lamivudine/dolutegravir antiretroviral therapy in persons with HIV: real-life data from the ICONA Foundation cohort
2025
·
Alessandra Vergori
, Alessandro Cozzi-Lepri
, et al.
·
Journal of Antimicrobial Chemotherapy
·
4
Risk of clinical events in virologically suppressed people with HIV switching to a two-drug regimen vs. remaining on a three-drug regimen: a target trial emulation
2025
·
Cristina Mussini
, Andrea Giacomelli
, et al.
·
EClinicalMedicine
·
4
PDF
Decrease in drug-drug interactions between antiretroviral drugs and concomitant therapies in older people living with HIV-1 switching to bictegravir/emtricitabine/tenofovir alafenamide.
2025
·
Leonardo Calza
, Maddalena Giglia
, et al.
·
PubMed
·
3
PDF
Two-fold increased risk of cardiovascular events in people with MDR HIV: a matched cohort analysis with data from the PRESTIGIO registry
2024
·
Tommaso Clemente
, Sara Diotallevi
, et al.
·
Journal of Antimicrobial Chemotherapy
·
2
PDF
Long-acting injectable antiretrovirals for HIV treatment in the ICONA cohort: physicians’ and nurses’ points of view
2024
·
A Cingolani
, A Tavelli
, et al.
·
Journal of Antimicrobial Chemotherapy
·
2
SAT-587-YI Distinct patterns of HBsAg isoform reflect viral activity and characterize disease stage in the setting of chronic HDV infection
2026
·
Ilaria Grossi
, Caterina Tramontozzi
, et al.
·
Journal of Hepatology
·
1
Evaluation of HIV-1 DNA resistance evolution in highly treatment-experienced and multi-resistant individuals under suppressive antiretroviral therapy: a longitudinal study from the PRESTIGIO Registry
2025
·
D Armenia
, G Marchegiani
, et al.
·
Journal of Antimicrobial Chemotherapy
·
1
PDF
Fever of unknown origin (FUO) FADOI-SIMIT Italian registry: can demographics, comorbidities, and clinical variables predict the etiology of classic FUO?—a prospective Italian study
2025
·
Roberto Luzzati
, Verena Zerbato
, et al.
·
Internal and Emergency Medicine
·
1
Selected comorbidities and the probability of ART switch in PWH with undetectable HIV-RNA: a retrospective analysis in Italy
2025
·
Alessandro Cozzi-Lepri
, Alessandro Tavelli
, et al.
·
Journal of Antimicrobial Chemotherapy
·
1
Burden of Hepatitis D Virus infection in Italy: final results from the HDV Describe study
2025
·
G.P. Caviglia
, A. Loglio
, et al.
·
Digestive and Liver Disease
·
1
SC-23 Changes in bone mineral density in antiretroviral therapy-naive people living with HIV-1 aged over 50 years and starting bictegravir/emtricitabine/tenofovir alafenamide
2024
·
L Calza
, M Giglia
, et al.
·
Sexually Transmitted Infections
·
1
PDF
Burden of Hepatitis D Virus infection in Italy: interim results from a prospective multicentre nationwide study
2024
·
G.P. Caviglia
, P. Colombatto
, et al.
·
Digestive and Liver Disease
·
1
Virological outcomes, resistance profile and viral evolution of lenacapavir-based regimens in heavily treatment-experienced people: data from the PRESTIGIO Registry
2026
·
Maria Mercedes Santoro
, Daniele Spalletta
, et al.
·
Journal of Antimicrobial Chemotherapy
PDF
Higher Risk of Loss to Follow-up Among Transgender People With HIV in Italy: Findings From the ICONA Cohort
2026
·
Davide Moschese
, Marco Muccio
, et al.
·
Open Forum Infectious Diseases
OC11 Chronic HDV infection is characterized by distinct profiles of HBsAg isoforms underlying different disease stages
2026
·
I Grossi
, C Tramontozzi
, et al.
·
Sexually Transmitted Infections
PDF
Show more works
View as search
Works count:
36
Citation count:
173
H-index:
6
I10-index:
4
Year
Topic
Type